Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

Mumbai: The Proton Therapy Facility at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of the ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

What: On today, February 23, 2026, the Maryland Proton Treatment Center (MPTC) will celebrate a momentous milestone – fighting cancer for +10 years with proton therapy. To commemorate this occasion, ...

Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...

SOMERSET, N.J., Feb. 13, 2026 /PRNewswire/ -- In recognition of National Cancer Prevention Month, ProCure Proton Therapy Center is urging men to prioritize prostate-specific antigen (PSA) ...

Phase 2 study shows proton therapy kept 79.1% of patients progression free at five years and limited severe side effects compared with older radiation data. Investigators at Mass General Brigham ...

Salvage focal therapy may offer durable localized prostate cancer control for up to 10 years compared with salvage radical prostatectomy for radiorecurrent disease. For patients with localized, biopsy ...

In a trial, the ProFocal device for intermediate-risk prostate tumor ablation had an 84% treatment success rate with low morbidity. Cooled laser focal therapy ablation using a novel device (ProFocal®; ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The health systems combined will ...

On World Cancer Day, Wellness Wednesday is spotlighting a cutting-edge cancer treatment now available in the Oklahoma City metro: proton therapy. We spoke with Dr. Kole Melton, a radiation oncologist ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...